We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+0.73%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$24.1B
AUM Growth
+$1.97B
Cap. Flow
+$2.05B
Cap. Flow %
8.49%
Top 10 Hldgs %
10.49%
Holding
3,709
New
1,118
Increased
953
Reduced
622
Closed
747

Sector Composition

Rank Sector Weight
1 Healthcare 20.28%
2 Financials 16.56%
3 Technology 13.74%
4 Consumer Discretionary 11.01%
5 Communication Services 4.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HEPS
2401
D-Market Electronic Services & Trading
HEPS
$1.02B
$477K ﹤0.01%
+69,514
New +$757K
RMCOW icon
2402
CALL
Royalty Management Holding Warrant
RMCOW
$1.46M
$474K ﹤0.01%
+48,005
New +$30.7K
FHN icon
2403
First Horizon
FHN
$12.2B
$473K ﹤0.01%
+29,047
New +$463K
MBWM icon
2404
Mercantile Bank Corp
MBWM
$1.04B
$473K ﹤0.01%
+14,765
New +$457K
GWB
2405
DELISTED
Great Western Bancorp, Inc.
GWB
$471K ﹤0.01%
+14,366
New +$443K
DRD
2406
DRDGold
DRD
$1.75B
$470K ﹤0.01%
58,117
-18,007
-24% -$174K
FBT icon
2407
First Trust NYSE Arca Biotechnology Index Fund
FBT
$2.84B
$470K ﹤0.01%
2,833
+480
+20% +$82K
WING icon
2408
Wingstop
WING
$3.8B
$470K ﹤0.01%
2,873
-6,858
-70% -$1.16M
XPOA.WS
2409
CALL
DELISTED
DPCM Capital, Inc. Warrants, each whole warrant exercisable for one share of Class A Common Stock at
XPOA.WS
$467K ﹤0.01%
+47,788
New +$40.6K
EEM icon
2410
iShares MSCI Emerging Markets ETF
EEM
$27.5B
$466K ﹤0.01%
9,244
-96,499
-91% -$5.02M
UAN icon
2411
CVR Partners
UAN
$1.3B
$466K ﹤0.01%
+6,686
New +$403K
ANSS
2412
DELISTED
Ansys
ANSS
$464K ﹤0.01%
1,363
-9,002
-87% -$3.25M
KLR
2413
DELISTED
Kaleyra, Inc.
KLR
$464K ﹤0.01%
12,053
-46,374
-79% -$1.83M
BGSF icon
2414
BGSF Inc
BGSF
$57.4M
$463K ﹤0.01%
36,207
+12,920
+55% +$165K
GABC icon
2415
German American Bancorp
GABC
$1.93B
$462K ﹤0.01%
11,955
-10,398
-47% -$387K
RTL
2416
DELISTED
The Necessity Retail REIT, Inc. Class A Common Stock
RTL
$461K ﹤0.01%
57,376
-347,630
-86% -$2.94M
FTAAW
2417
CALL
DELISTED
FTAC Athena Acquisition Corp. Warrant
FTAAW
$460K ﹤0.01%
+46,512
New +$56.9K
GIIXW
2418
CALL
DELISTED
Gores Holdings VIII, Inc. Warrant
GIIXW
$460K ﹤0.01%
46,870
OI icon
2419
O-I Glass
OI
$1.18B
$458K ﹤0.01%
+32,061
New +$480K
OR icon
2420
OR Royalties Inc
OR
$5.53B
$457K ﹤0.01%
+40,720
New +$510K
XENE icon
2421
Xenon Pharmaceuticals
XENE
$6.1B
$456K ﹤0.01%
29,803
+19,350
+185% +$336K
TWCBW
2422
CALL
DELISTED
Bilander Acquisition Corp. Warrant
TWCBW
$456K ﹤0.01%
+47,010
New +$58.6K
CMPS
2423
Compass Pathways
CMPS
$1.47B
$453K ﹤0.01%
15,170
-9,533
-39% -$320K
FONR
2424
DELISTED
Fonar
FONR
$452K ﹤0.01%
29,231
-1,996
-6% -$33.8K
SFL icon
2425
SFL Corp
SFL
$1.61B
$451K ﹤0.01%
53,846
-338,947
-86% -$2.57M

Similar funds

Marshall Wace's Q3 2021 Portfolio in Review

As of Q3 2021, Marshall Wace held 3,709 positions worth $24.1B, up 8.9% from $22.1B the previous quarter. Its ten largest holdings account for 10% of the portfolio.

Marshall Wace deployed $2.05B of net new capital in Q3 2021, opening 1,118 new positions and adding to 953 existing holdings. Its largest new stake was SkinHealth Systems: 4,113,430 shares worth $107M.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Biogen, an estimated $210M trimmed.

  • Marshall Wace's largest Q3 2021 buy was SkinHealth Systems: 4,113,430 shares worth $107M.
  • Marshall Wace added most to Uber in Q3 2021, an estimated $127M increase.
  • Marshall Wace's biggest Q3 2021 reduction was Biogen, cutting an estimated $210M.
  • Marshall Wace fully exited Vipshop in Q3 2021, selling an estimated $58.7M.
  • Marshall Wace's ten largest holdings make up 10% of its $24.1B portfolio in Q3 2021.
  • Marshall Wace opened 1,118 new positions and closed 747 in Q3 2021.
  • Marshall Wace's portfolio value rose 8.9% quarter-over-quarter to $24.1B.

Based on Marshall Wace's 13F filing for Q3 2021, filed 15 Nov 2021.